![[url=file_closeup.php?id=84174875] [img]file_thumbview_approve/84174875/2/[/img] [url=file_closeup.php?id=62711664] [img]file_thumbview_approve/62711664/2/[/img] [url=file_closeup.php?id=59795748] [img]file_thumbview_approve/59795748/2/[/img] [url=file_closeup.php?id=21984986] [img]file_thumbview_approve/21984986/2/[/img] [url=file_closeup.php?id=41886470] [img]file_thumbview_approve/41886470/2/[/img] [url=file_closeup.php?id=41880126] [img]file_thumbview_approve/41880126/2/[/img] [url=file_closeup.php?id=41882644] [img]file_thumbview_approve/41882644/2/[/img] [url=/search/lightbox/5542306] - the Capitol LB - [img]/file_thumbview_approve/6581839/2/[/img]](https://www.ptabwatch.com/wp-content/uploads/sites/630/2016/07/US-Capitol-Hill-DC-150x150.jpg)
In Cuozzo Speed Technologies, LLC v. Lee, the Supreme Court recognized that a “district court may find a patent claim to be valid, and the agency may later cancel that claim in its own review.” The Court also recognized that because of the different evidentiary burdens in court versus before the agency—the Patent Office—“the possibility of inconsistent results is inherent to Congress’[s] regulatory design.” Is that inconsistency sensible? As good a case as any to consider that question involves a global pharmaceutical company, one of its top-selling drug products, and a patent it owns that covers the administration of that drug product.
Continue Reading The Possibility of Inconsistent Results Inherent to Congress’s Design of AIA Trial Reviews

The much anticipated argument in Cuozzo Speed Technologies, LLC v. Lee occurred Monday, April 25, 2016 before the
The Federal Circuit has rejected for the third time efforts by the Director of the PTO to preclude appellate review of whether challenged patent claims were properly deemed “covered business methods,” and thereby subject to CBM review. Previously, in Versata Development Group, Inc. v. SAP America, Inc., the Federal Circuit concluded that its jurisdiction to hear appeals of the PTAB’s final written decisions empowered it to examine if challenged claims qualified for CBM review (we reported
The AIA explicitly bestows the USPTO Director with the authority to institute IPRs and the PTAB with the authority to decide the ultimate question of patent validity. The Director delegated the authority to institute IPRs to the Board, but is it proper to assign the decision to the same APJs that render a final decision? A split panel at the Federal Circuit held that neither the AIA nor the Constitution precludes the same PTAB panel from rendering both institution and final decisions. Ethicon Endo-Surgery, Inc. v. Coviden LP, No. 2014-1771 (Fed. Cir. 2016).
On January 15, 2016, the United States Supreme Court agreed to consider whether it is appropriate to give claims challenged in inter partes review their “broadest reasonable construction.” See 
The PTAB recently issued an order applying the estoppel provision of the AIA (35 U.S.C. § 325(e)(1)) to dismiss a petitioner from covered business method (CBM) patent review proceedings a few days before a consolidated final hearing. 
The purported culprits? The PTAB and the America Invents Act’s newly enacted Inter Partes Review and Covered Business Method Review. “